Asia Pacific Cancer Tissue Diagnostics Market

The Asia Pacific Cancer tissue diagnostics market is expected to reach US$ 730.09 Mn in 2027 from US$ 410.78 Mn in 2018. The market is estimated to grow with a CAGR of 6.9% from 2019-2027.

Developing countries in Asia have limited or fewer healthcare resources and hence use different strategies to diagnose different types of cancer. In developing poor countries, most of the population relies on the public healthcare systems as the healthcare infrastructures are poor in these countries. Despite advancements in the pharmaceuticals and treatment procedures, cancer is diagnosed in the advanced stages in developing countries as early detection or diagnosis, and treatment is not efficiently promoted.

Many of the low- and middle-income countries (LMICs) in Asia have very poor healthcare services, and the cancer burden is substantial in these countries. Despite the increasing burden of cancer, the disease is still a low priority in healthcare planning and expenditure in most of the Asian LMICs.

Furthermore, South Asian women show lower uptake of breast screening services, especially those from lower socioeconomic groups. Screening rates are low in South Asian populations because they have poor knowledge and awareness of cancer, low community awareness, poor communication between patients and healthcare professionals, and limited access to cancer health services. Thus cancer mortality is high in LMICs as compared with high-income countries (HICs).

There has been rise in cancer incidence and mortality rates in China, making cancer the leading cause of death since 2010 in the country. Much of the rising burden is due to population growth, aging population, and socio-demographic changes. As per data revealed by the WHO, an approximate 4.3 million new cases of cancer were detected as well as 2.9 million cancer deaths were recorded in the country during the year 2018. The prevalence of cancer, coupled with various technological advancements for detection is anticipated to fuel the growth of the market in China during the forecast period.

Rest of Asia Pacific Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)

Get more information on this report Request Free Sample PDF

Asia Pacific Cancer Tissue Diagnostics Strategic Insights

Strategic insights for the Asia Pacific Cancer Tissue Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Cancer Tissue Diagnostics Report Scope

Asia Pacific Cancer Tissue Diagnostics Regional Insights

The geographic scope of the Asia Pacific Cancer Tissue Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

ASIA PACIFIC CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION

By Test Type

• Immunohistochemical Tests
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Others
• In Situ Hybridization Tests
  • Breast Cancer
  • Lung Cancer
  • Bladder Cancer
  • Others

By Country

• China
• Japan
• India
• Australia
• South Korea

Companies Mentioned

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Bio Rad Laboratories Inc.
• Abbott
• Enzo Life Sciences, Inc.
• Agilent Technologies, Inc.
• Cancer Genetics Inc.
• Merck KGaA (Sigma-Aldrich Co. LLC)
• Danaher Corporation
• Abcam plc.